Fortrea Holdings Inc. (FTRE) has a MoatMap StockRank of 59/100 based on Quality (29/100), Value (45/100), and Momentum (70/100) factor scores. The current signal is HOLD. Fortrea is a CRO spun off from Labcorp with weak profitability (Q-score: 29) and significant operational headwinds, making it a turnaround story we prefer to avoid.
Fortrea Holdings Inc. is a global contract research organization (CRO) providing clinical development, patient access, and post-approval services to pharmaceutical and biotechnology companies. Its extensive global footprint, deep scientific and therapeutic expertise, and integrated suite of services position it as a critical partner in accelerating drug development for biopharma clients. Fortrea is a significant independent CRO in the drug development ecosystem.
| Price | $16.88 |
| Market Cap | $1.4B |
| P/E (Forward) | 16.02 |
| Price/Book | 2.85 |
| Return on Equity | -64.5% |
| Return on Invested Capital | -49.5% |
| Debt/Equity | 212.70 |
| Gross Margin | 18.9% |
| Operating Margin | 0.5% |
| Revenue Growth | -2.3% |
| Free Cash Flow | $286M |
Fortrea Holdings Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).